Effects of sunitinib on endothelial dysfunction, metabolic changes, and cardiovascular risk indices in renal cell carcinoma

BACKGROUND: Sunitinib is a standard treatment for metastatic renal cell carcinoma (RCC). Currently, the data available on the effects of sunitinib on endothelial dysfunction, metabolic changes, and cardiovascular (CV) risk factors are limited, and we aimed to evaluate these aspects in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Silvia, Amabile, Maria Ida, Mazzaferro, Sandro, Mitterhofer, Anna Paola, Mazzarella, Angelo, Galani, Alessandro, Imbimbo, Giovanni, Cianci, Rosario, Pasquali, Marzia, Molfino, Alessio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286450/
https://www.ncbi.nlm.nih.gov/pubmed/32270594
http://dx.doi.org/10.1002/cam4.2910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286450/
https://www.ncbi.nlm.nih.gov/pubmed/32270594
http://dx.doi.org/10.1002/cam4.2910

Ejemplares similares